Literature DB >> 16045837

Angiogenesis in psoriasis and psoriatic arthritis: clues to disease pathogenesis.

Tai Teck Leong1, Ursula Fearon, Douglas J Veale.   

Abstract

Psoriasis is a common chronic dermatosis occurring in 2% of the population and associated with an inflammatory arthritis--psoriatic arthritis (PsA)--in up to 40% of cases. PsA accounts for approximately 15% of patients attending early synovitis clinics, therefore it represents the second most common diagnostic category after rheumatoid arthritis. There are a number of common pathogenic features that link the skin and the joint inflammatory processes. Angiogenesis appears to be a fundamental inflammatory response early in the pathogenesis and significant abnormalities of vascular morphology and angiogenic growth factors have been described in psoriasis and PsA. This paper will explore the recent published evidence to support the hypothesis that dysregulated angiogenesis provides a primary pathogenic mechanism in psoriasis skin and in the PsA joint.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16045837     DOI: 10.1007/s11926-005-0044-5

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  29 in total

1.  Active and inactive edges of psoriatic plaques: identification by tracing and investigation by laser--Doppler flowmetry and immunocytochemical techniques.

Authors:  S M Hull; M Goodfield; E J Wood; W J Cunliffe
Journal:  J Invest Dermatol       Date:  1989-06       Impact factor: 8.551

2.  Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis.

Authors:  R J Reece; J D Canete; W J Parsons; P Emery; D J Veale
Journal:  Arthritis Rheum       Date:  1999-07

3.  A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis.

Authors:  A D Fraser; A W R van Kuijk; R Westhovens; Z Karim; R Wakefield; A H Gerards; R Landewé; S D Steinfeld; P Emery; B A C Dijkmans; D J Veale
Journal:  Ann Rheum Dis       Date:  2004-11-04       Impact factor: 19.103

4.  Signal transduction pathways involved in rheumatoid arthritis synovial fibroblast interleukin-18-induced vascular cell adhesion molecule-1 expression.

Authors:  Jacques C M Morel; Christy C Park; Kui Zhu; Pawan Kumar; Jeffrey H Ruth; Alisa E Koch
Journal:  J Biol Chem       Date:  2002-07-08       Impact factor: 5.157

5.  Ultrastructure of the capillary loops in the dermal papillae of psoriasis.

Authors:  I M Braverman; A Yen
Journal:  J Invest Dermatol       Date:  1977-01       Impact factor: 8.551

6.  Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis.

Authors:  Juan D Cañete; José L Pablos; Raimon Sanmartí; Carmen Mallofré; Sara Marsal; Joan Maymó; Jordi Gratacós; Jovita Mezquita; Cristobal Mezquita; Maria C Cid
Journal:  Arthritis Rheum       Date:  2004-05

7.  Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease.

Authors:  S M Jones; J B Armas; M G Cohen; C R Lovell; G Evison; N J McHugh
Journal:  Br J Rheumatol       Date:  1994-09

8.  Dermatological manifestations in psoriatic arthritis: a follow-up study.

Authors:  V Wright; M C Roberts; A G Hill
Journal:  Acta Derm Venereol       Date:  1979       Impact factor: 4.437

9.  Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal.

Authors:  L E Benjamin; D Golijanin; A Itin; D Pode; E Keshet
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

10.  Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study.

Authors:  Amber Y Goedkoop; Maarten C Kraan; Daisy I Picavet; Menno A de Rie; Marcel B M Teunissen; Jan D Bos; Paul P Tak
Journal:  Arthritis Res Ther       Date:  2004-05-26       Impact factor: 5.156

View more
  15 in total

1.  A histomorphometric analysis of synovial biopsies from individuals with Gulf War Veterans' Illness and joint pain compared to normal and osteoarthritis synovium.

Authors:  F Pessler; L X Chen; L Dai; C Gomez-Vaquero; C Diaz-Torne; M E Paessler; C Scanzello; N Cakir; E Einhorn; H R Schumacher
Journal:  Clin Rheumatol       Date:  2008-04-15       Impact factor: 2.980

Review 2.  Spatiotemporal control over growth factor signaling for therapeutic neovascularization.

Authors:  Lan Cao; David J Mooney
Journal:  Adv Drug Deliv Rev       Date:  2007-08-16       Impact factor: 15.470

3.  Transactivation of the receptor-tyrosine kinase ephrin receptor A2 is required for the low molecular weight hyaluronan-mediated angiogenesis that is implicated in tumor progression.

Authors:  Frances E Lennon; Tamara Mirzapoiazova; Nurbek Mambetsariev; Bolot Mambetsariev; Ravi Salgia; Patrick A Singleton
Journal:  J Biol Chem       Date:  2014-07-14       Impact factor: 5.157

4.  Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis.

Authors:  Helia B Schonthaler; Reto Huggenberger; Stefanie K Wculek; Michael Detmar; Erwin F Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-07       Impact factor: 11.205

Review 5.  Role of the endothelium in inflammatory bowel diseases.

Authors:  Walter E Cromer; J Michael Mathis; Daniel N Granger; Ganta V Chaitanya; J Steven Alexander
Journal:  World J Gastroenterol       Date:  2011-02-07       Impact factor: 5.742

6.  Characterization of CCL19 and CCL21 in rheumatoid arthritis.

Authors:  Sarah R Pickens; Nathan D Chamberlain; Michael V Volin; Richard M Pope; Arthur M Mandelin; Shiva Shahrara
Journal:  Arthritis Rheum       Date:  2011-04

Review 7.  Role of lymphatic vessels in tumor immunity: passive conduits or active participants?

Authors:  Amanda W Lund; Melody A Swartz
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-09-11       Impact factor: 2.673

Review 8.  Hyaluronan regulation of endothelial barrier function in cancer.

Authors:  Patrick A Singleton
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

9.  Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor.

Authors:  Cornelia Halin; Hermann Fahrngruber; Josef G Meingassner; Guido Bold; Amanda Littlewood-Evans; Anton Stuetz; Michael Detmar
Journal:  Am J Pathol       Date:  2008-06-05       Impact factor: 4.307

10.  Psoriatic Arthritis during Treatment with Bevacizumab for Anaplastic Oligodendroglioma.

Authors:  D Graceffa; E Maiani; A Pace; F M Solivetti; F Elia; C De Mutiis; C Bonifati
Journal:  Case Rep Rheumatol       Date:  2012-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.